戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ry efficiency compared to the gold standard, Lipofectamine.
2 ls, an 8-fold increase over that mediated by Lipofectamine.
3 ompared to the commercial transfection agent Lipofectamine.
4 hose transfected with plasmid complexed with Lipofectamine.
5 d in the native form or when formulated with lipofectamine.
6  with the routinely used transfecting agent, lipofectamine.
7  DCs, which were enhanced by the presence of lipofectamine.
8  human fibrosarcoma HT-1080 fibroblasts with lipofectamine.
9 an or comparable to DMRIE-C, Lipofectin, and Lipofectamine.
10 ervals of MAP(280-299)p2p30 in Lipofectin or Lipofectamine.
11 itopes in Montanide's ISA51, Lipofectin, and Lipofectamine.
12 ne or in the presence of pULI100 plasmid and lipofectamine.
13                  Commercial reagents such as Lipofectamine 2000 and FuGENE HD are widely used for the
14                                              Lipofectamine 2000 and PEI 40k formed the most stable DN
15 onger nanofiber micelleplexes as well as the Lipofectamine 2000 control.
16                                  Compared to Lipofectamine 2000, a commercial transfection agent, LNP
17 ells or cells transfected with VEGF by using Lipofectamine 2000, a leading commercial reagent.
18  provide methods for genetic manipulation by Lipofectamine 2000, electroporation or lentivirus and su
19 m arsenite (NaAsO2), cycloheximide (CHX) and Lipofectamine 2000-mediated transfection of phosphorothi
20 oxicity compared with commercially available lipofectamine 2000.
21 xhibited significant greater efficiency over Lipofectamine 2000.
22 hmark transfection reagents such as bPEI and Lipofectamine 2000.
23 l transfection reagents Polyethylenimine and Lipofectamine 2000.
24 s using transfection with the cationic lipid Lipofectamine 2000.
25 ed with branched polyethylenimine (bPEI) and Lipofectamine-2000.
26  cells using a new DNA transfection reagent, lipofectamine 3000, allowing assessment of their intrace
27 mimic, inhibitor or scrambled sequence using Lipofectamine 3000.
28 ificantly slower than the cells treated with LipofectAMINE alone or negative control siRNA.
29 ies in soft agar than did cells treated with LipofectAMINE alone or transfected with negative control
30 cted with HDGF-siRNA than cells treated with LipofectAMINE alone were able to invade across a Matrige
31  normal, organ-cultured human scalp HFs with lipofectamine and CDH3-specific or scrambled control siR
32 gth RyR2 was introduced into CHO cells using lipofectAmine and electroporation methods.
33 egradable poly(beta-amino ester)s as well as Lipofectamine and PEI to demonstrate that this assay has
34 -into primary human dermal fibroblasts using Lipofectamine, and assessed mRNA levels using RT-qPCR.
35 ransfer than cationic liposomes (lipofectin, lipofectamine, and DOTAP).
36 0 000 cells pretransfected in vitro by using lipofectamine as a positive control.
37 ive to the individual components prepared as lipofectamine complexes indicating the potential utility
38  levels when compared to polyethylenimine or lipofectamine complexes.
39 ult is achieved by random Brownian motion of Lipofectamine-containing vesicles within the cytoplasm.
40                                 We find that Lipofectamine, contrary to alternative formulations, is
41 editing efficiency, besting the state-of-art Lipofectamine CRISPRMax.
42 Brownian diffusion is an efficient route for Lipofectamine/DNA complexes to avoid metabolic degradati
43 l the intracellular trafficking mechanism of Lipofectamine/DNA complexes.
44 st cancer cells, and addition of a liposome, lipofectamine, further enhanced the transfection efficie
45 cantly improved transfection efficiency over Lipofectamine in serum-containing media.
46 than the common nonviral agents Fugene-6 and Lipofectamine in the presence of serum.
47 poptosis induced by poly(I:C) transfected by Lipofectamine (in-poly(I:C)) compared with the 12-fold h
48 cking of two cationic liposomes, DMRIE-C and Lipofectamine LTX, in CHO cells.
49                  PBAE-PEG/LNP was similar to Lipofectamine MessengerMAX followed by PBAE/LNP for mRNA
50                                              Lipofectamine MessengerMAX was inactive in vivo.
51 ls, similar to that mediated by the standard Lipofectamine method.
52                                            A lipofectamine preparation of the Zn(2+)-DNA complex disp
53 also showed lower cytotoxicity compared with Lipofectamine(R) 2000 and PEI 25 kDa in various cell typ
54 ytotoxicity compared to branched PEI 25 kDa, Lipofectamine(R) 2000 and, FuGENE(R) 6.
55  kDa in HeLa cells and 7.4 times higher than Lipofectamine(R) 2000 in H9C2 cell.
56 ed low cytotoxicity compared to bPEI 25k and Lipofectamine(R) 2000 in hMSCs.
57                                              Lipofectamine reagents are widely accepted as "gold-stan
58 s exotoxin gene in the presence of dl312 and lipofectamine resulted in marked breast cancer cell kill
59 eas the maximum gene silencing efficiency of Lipofectamine RNAiMAX was less than 60% and the ED50 was
60 11% after 72h post-transfection, better than Lipofectamine RNAiMax.
61 the absence of human serum, nanocapsules and lipofectamine silenced expression of CCR5-mCherry expres
62 less than 15% while siRNAs delivered through lipofectamine slightly knocked down the expression to 55
63 transfected replicon RNA for a given mass of Lipofectamine, the replicons were mixed with a "carrier"
64 nzyme knockdown nearly doubled from >30% for Lipofectamine to >60% for our best hit.
65 eduction in message expression compared with lipofectamine-transfected cells.
66 lenced by lentiviral infection and transient Lipofectamine transfection of cultured rat nodose gangli
67                                              LipofectAMINE transfection of the cDNAs resulted in high
68                                              Lipofectamine transfection of the conjugate into HSG cel
69    HSG cells treated with conjugate (without Lipofectamine transfection) exhibited a 50% reduction in
70 only after 2 W/cm(2) ultrasound exposure and lipofectamine transfection.